[14]Levy B, Paz-Ares L, Su W, et al. Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung can...
TROPION-Lung01研究涵盖了经治伴或不伴AGA的NSCLC患者,其中AGA人群包括了EGFR、ALK、ROS1、NTRK、BRAF、METex14或RET变异等多种驱动基因突变患者,且既往接受过1-2线靶向治疗和含铂化疗。Non-AGA患者则要求明确EGFR/ALK阴性,且没有已知的ROS1、NTRK、...
III期TROPION-Lung01研究显示,Dato-DXd治疗既往经治的晚期NSCLC较多西他赛可显著改善PFS(4.4 vs 3.7 个月,HR = 0.75,P = 0.004);且亚组分析提示,非鳞癌患者(HR = 0.63)与伴AGA患者(HR = 0.38)接受Dato-DXd治疗PFS获益更佳[5]。更早报告的I期TROPION-PanTumor01研究同样提示Dato-DXd在伴AGA晚期NSCLC 患者...
TROPION-PanTumor01 研究 NSCLC 队列初步验证了 Dato-DXd 在经治伴或不伴可靶向基因组异常(AGA)的 NSCLC 患者中的疗效和安全性,对于接受推荐剂量 6 mg/kg Q3W 治疗的患者,客观缓解率(ORR)为 26%,中位缓解持续时间(DOR)为 10.5 个月,中位 PFS 为 6.9 个月,中位总生存(OS)为 11.4 个月;最常见的治疗...
Dato-DXd组和多西他赛组均分别纳入234名NSQ NSCLC患者,其中两组AGA患者占比均为21%;两组分别有46%和44%的患者既往接受过≥2线治疗;有85%和86%的患者既往接受过PD-1/PD-L1抑制剂,两组所有患者几乎既往均接受过含铂化疗(99% vs 100%)。 图2. TL01研究中NSQ NSCLC患者的基线特征 ...
摘要号:556MO标题:A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer 信迪利单抗加西达本胺联合或不联合贝伐珠单抗治疗MSS/pMMR转移性结直肠癌患者的II期临床试验 ...
For cell migration ability analysis, the re-suspended cells were placed in to upper chamber without Matrigel. After incubation for 24 h in humidified atmosphere with 5% CO2, cells on the upper side of the insert membrane was completely removed using cotton swab. Inserts were fixed using 4% ...
近期,TROP2 ADC的代表性药物Datopotamab deruxtecan(Dato-DXd)治疗既往经治的伴可靶向基因组变异(AGA)的晚期非小细胞肺癌(NSCLC)患者的II期TROPION-Lung05研究结果正式发表于国际顶级医学期刊J Clin Oncol(IF=42.1)[1],进一步验证了Dato-DXd在该类患者中的应用价值。基于此,医脉通特邀中山大学附属第一医院...
Control mice received a 0.2 mL saline solution injection without cells. The mice were housed at 22–25 °C and 60–70% humidity, with ad libitum access to water and food. After 30 days, mice from each group were euthanized. Tumors were rinsed with PBS until blood-free and stored at ...
值得强调的是,EVOKE-01研究中鳞癌与非鳞癌亚组患者接受SG治疗相比多西他赛均无获益,而TROPION-Lung01研究显示非鳞癌患者,尤其AGA人群接受Dato-DXd治疗PFS显著获益,且OS获益趋势明显,同时Dato-DXd治疗的ORR提升了一倍以上。这些结果共同强调了Dato-DXd在既往靶向、免疫治疗耐药的非鳞状NSCLC后线治疗潜力。